inc research/inventiv health has become syneos health, the only fully integrated end-to-end clinical and commercial solution organization. we are purpose-built for biopharmaceutical acceleration, creating better, smarter, faster ways to help clients navigate an increasingly complex marketplace. our new business addresses today’s market realities through clinical and commercial sharing expertise and data and insights to meet the needs of emerging and large global biopharmaceutical companies.
Company profile
Ticker
SYNH
Exchange
Website
CEO
Michael Bell
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Icon • Medpace • Incyte • Zymergen • OmniAb • SomaLogic ...
Former names
INC Research Holdings, Inc.
SEC CIK
Corporate docs
Subsidiaries
Addison Whitney LLC • Allidura Communications LLC • BioSector 2 LLC • Boco Digital Media, LLC • Cadent Medical Communications, LLC • Caerus Marketing Group, LLC • Chamberlain Communications Group LLC • Chandler Chicco Agency, L.L.C. • Genicos, LLC • Gerbig Snell/Weisheimer Advertising, LLC ...
IRS number
273403111
SYNH stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
10 Oct 23
8-K
Syneos Health Appoints Colin Shannon as Chief Executive Officer
3 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Sep 23
25-NSE
Exchange delisting
28 Sep 23
8-K
Entry into a Material Definitive Agreement
28 Sep 23
8-K
Regulation FD Disclosure
6 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
Transcripts
SYNH
Earnings call transcript
2022 Q4
16 Feb 23
SYNH
Earnings call transcript
2022 Q3
4 Nov 22
SYNH
Earnings call transcript
2022 Q2
2 Aug 22
SYNH
Earnings call transcript
2022 Q1
29 Apr 22
SYNH
Earnings call transcript
2021 Q4
17 Feb 22
SYNH
Earnings call transcript
2021 Q3
3 Nov 21
SYNH
Earnings call transcript
2021 Q2
9 Aug 21
SYNH
Earnings call transcript
2021 Q1
2 May 21
SYNH
Earnings call transcript
2020 Q4
18 Feb 21
SYNH
Earnings call transcript
2020 Q3
1 Nov 20
Latest ownership filings
4
Alfonso G Zulueta
28 Sep 23
4
David S. Wilkes
28 Sep 23
4
Matthew E. Monaghan
28 Sep 23
4
Kenneth F Meyers
28 Sep 23
4
WILLIAM E KLITGAARD
28 Sep 23
4
Bernadette Connaughton
28 Sep 23
4
Barbara W. Bodem
28 Sep 23
4
John M. Dineen
28 Sep 23
4
Donna Hildebrand Kralowetz
28 Sep 23
4
Christian Tucat
28 Sep 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 82.28 mm | 82.28 mm | 82.28 mm | 82.28 mm | 82.28 mm | 82.28 mm |
Cash burn (monthly) | 9.59 mm | 1.98 mm | (no burn) | (no burn) | 11.23 mm | (no burn) |
Cash used (since last report) | 94.65 mm | 19.50 mm | n/a | n/a | 110.77 mm | n/a |
Cash remaining | -12.37 mm | 62.78 mm | n/a | n/a | -28.50 mm | n/a |
Runway (months of cash) | -1.3 | 31.8 | n/a | n/a | -2.5 | n/a |
Institutional ownership, Q3 2023
0.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 1 |
Closed positions | 299 |
Increased positions | 3 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 77.11 mm |
Total shares | 297.27 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Skandinaviska Enskilda Banken AB | 137.50 k | $5.91 mm |
Public Employees Retirement Association Of Colorado | 84.17 k | $11.79 mm |
DekaBank Deutsche Girozentrale | 40.00 k | $1.72 mm |
Handelsbanken Fonder AB | 18.51 k | $796.00 k |
Natixis Advisors | 14.57 k | $626.00 k |
BCS Barclays | 1.16 k | $50.00 k |
Nomura Asset Management | 1.14 k | $49.00 mm |
IFP Advisors | 96.00 | $4.13 mm |
Thrivent Trust Co of Tennessee | 51.00 | $2.00 k |
International Assets Investment Management | 43.00 | $1.85 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Sep 23 | Keefe Michelle | Class A Common Stock | Sale back to company | Dispose D | No | No | 0 | 157,504 | 0.00 | 0 |
28 Sep 23 | Keefe Michelle | Class A Common Stock | Sale back to company | Dispose D | No | No | 43 | 35,938 | 1.55 mm | 157,504 |
28 Sep 23 | Michael Lee Brooks | Class A Common Stock | Sale back to company | Dispose D | Yes | No | 43 | 3,410 | 146.63 k | 0 |
28 Sep 23 | Michael Lee Brooks | Class A Common Stock | Sale back to company | Dispose D | No | No | 0 | 107,127 | 0.00 | 0 |
28 Sep 23 | Michael Lee Brooks | Class A Common Stock | Sale back to company | Dispose D | No | No | 43 | 14,906 | 640.96 k | 107,127 |
28 Sep 23 | Bonello Michael J. | Class A Common Stock | Sale back to company | Dispose D | No | No | 0 | 51,433 | 0.00 | 0 |
28 Sep 23 | Christian Tucat | Class A Common Stock | Sale back to company | Dispose D | No | No | 0 | 39,296 | 0.00 | 0 |
28 Sep 23 | Christian Tucat | Class A Common Stock | Sale back to company | Dispose D | No | No | 43 | 11,348 | 487.96 k | 39,296 |
28 Sep 23 | Olefson Jonathan | Class A Common Stock | Sale back to company | Dispose D | No | No | 0 | 50,258 | 0.00 | 0 |
28 Sep 23 | Olefson Jonathan | Class A Common Stock | Sale back to company | Dispose D | No | No | 43 | 14,368 | 617.82 k | 50,258 |
Press releases
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting
12 Apr 24
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone)
8 Apr 24
NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers
27 Feb 24